Omanta
New accelerator entry · 2026-08-03 · the record
In their words
Omanta is a personalized research lab for patients who have exhausted standard options, want to prepare proactively for recurrence, or are living with an unresolved diagnosis. We direct the full operational infrastructure, personnel, expertise, and technology of a large research program toward understanding and addressing the challenges of individual patients across oncology, rare disease, and undiagnosed conditions. For clinicians, we act as a collaborative partner, providing a living roadmap for ongoing patient care built on a rigorous and evolving scientific evidence base. We fully operationalize patient-specific research programs, covering tissue logistics, diagnostic follow-up, data integration, multiomic analysis, therapeutic strategy development, and more. Omanta brings context and clarity to complex cases, helping clinicians see more of the scientific picture as they decide how best to care for their patients.
What the record says
Co-Founder and CEO of Omanta. PhD in Cancer Bioinformatics from UCLA, biomedical researcher at Broad Institute and Harvard. Spearheaded personalized therapeutic campaigns for patients creating personalized vaccines, immunotherapies, and radioligands. 10+ years in personalized medicine. Fueled by the belief that the future of Health is deeply personalized.
Co-founder & CSO at Omanta, working with patients to turn frontier science into personalized treatment strategies. Harvard Chemical Biology PhD in 3 years; identified a druggable ulcerative colitis mechanism that led to a multimillion-dollar GSK collaboration. Built and directed a multimillion-dollar rare cancer program for one patient, coordinating researchers, physicians, biotechs, and drug developers. Led strategies for 12+ complex patients after standard options were exhausted.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
Against the 209 companies on file from Summer 2026. Median team 2, largest 30.
The nearest companies on file from the same batch, side by side with this one.
| Company | Batch | Sectors | Listed |
|---|---|---|---|
| Frontier Computing | Summer 2026 | Artificial Intelligence, Hard Tech, Hardware | 2026-08-31 |
| Ethos Space Resources | Summer 2026 | Hard Tech, Exascale Computing, Energy | 2026-08-23 |
| Spectre Intelligence | Summer 2026 | Biotech, Investing, Trading | 2026-08-22 |
| Edgerun | Summer 2026 | Robotics, Defense | 2026-08-21 |
| Allia Health | Summer 2026 | Artificial Intelligence, Healthcare, Mental Health | 2026-08-19 |
| Omanta (this page) | Summer 2026 | Digital Health, Healthcare, Health & Wellness | 2026-08-03 |
Click a column heading to sort. Comparison is against records held here, not against every company that exists.
The full profile
The rest of this profile is open on any paid or trial plan
It costs no credits. It is a plan check and nothing else.
- Source Check — verify Alfredo Gonzalez's other claims against the registers that hold them.
- INVEST — compare this company against the peers above, on the numbers.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Alfredo Gonzalez for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist OmantaYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Omanta: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry. Figures are read directly from the source record; names have not been matched against other people.